When the Final Pathology Report Says Stage III After You Were Told It Looked Like Stage II — Why Tumor Histology and Lymph Node Counts Sit in Different Columns, and How to Reread the Report Before Adjuvant Chemotherapy

The final pathology report handed to you at the first post-operative clinic visit is not the same document as the stage you were quoted before surgery. The stage discussed before and during an operation is the clinical stage (cTNM), based on endoscopy, imaging such as CT, and what the surgical team could see. What is written on the final report is the pathological stage (pTNM), assigned after the removed stomach and surrounding tissue are cut into many sections and examined one by one under a microscope. A mismatch between the two numbers is not unusual, and it does not by itself mean the earlier assessment was careless. The two assessments use different tools and see different amounts of tissue.

Lymph nodes are especially hard to judge by imaging alone. CT estimates involvement from a node's size, shape, and enhancement pattern, but a small node can still contain cancer cells, while an enlarged one may simply reflect inflammation. Reports usually list nodes as a pair: the number with metastasis over the total number retrieved. Attention naturally goes to the first figure, but the second matters too. In gastric cancer, retrieving at least a certain number of nodes (commonly cited as 16) is considered necessary for staging to be reliable, and wider dissections often yield considerably more. Another point that is easy to miss: nodal classification in gastric cancer is based on how many nodes are involved, not how large they are. The categories run in bands — roughly 1 to 2, 3 to 6, 7 to 15, and 16 or more — and these bands combine with T (how deeply the tumor invaded the stomach wall) to produce the final stage. This is why a tumor that appeared to invade shallowly can still fall into a higher stage group when many nodes are involved.

The histologic subtype named on the report belongs to yet another column. Signet ring cell carcinoma is a microscopic description: mucin fills the cell and pushes the nucleus to one side, producing a ring-like appearance. Current classifications group it under poorly cohesive carcinoma, and in the older Lauren system it often corresponds to the diffuse type. Because the cells tend to spread through tissue individually rather than forming a discrete mass, the border may not be sharply visible on endoscopy or imaging, which makes the pre-operative estimate of extent harder. This is one reason a stage can shift upward on final pathology. Still, a subtype name on its own does not determine what lies ahead. Stage, whether clear resection margins were achieved, the presence of lymphovascular or perineural invasion, age, overall condition, and response to treatment all enter the picture together.

A recurrence percentage quoted in the consultation room is a population statistic. Even for the same stage, the figure shifts depending on when and where the data were collected and what treatment those patients received, and it usually refers to a defined period such as five years after surgery. Most importantly, a number drawn from patients who received adjuvant chemotherapy means something quite different from one drawn from those who did not. Rather than holding onto the number itself, it is more useful to ask what conditions produced it.

Here is a practical order for the weeks before adjuvant treatment begins. First, request a copy of the pathology report and keep it. The written items are far more useful than a spoken stage in later consultations, referrals, and paperwork. Second, mark in advance what to check on it: depth of invasion (pT), the number of involved nodes alongside the total retrieved (pN), whether margins were free of tumor, whether lymphovascular or perineural invasion was noted, and whether markers such as MSI or MMR status — which are sometimes considered in treatment decisions — are included. If they are absent, you can ask whether additional testing is possible. Third, CT scans and blood tests scheduled before chemotherapy often serve to re-establish a baseline after surgery rather than signaling that something has worsened; knowing this can ease the waiting period. Fourth, start a dated log of weight and daily food intake. After gastrectomy the volume the stomach can hold at one time is reduced and weight loss is common, and this record becomes concrete evidence for adjusting chemotherapy intensity and nutrition support. Paper remembers when the kilograms came off more accurately than memory does. Finally, matters that are decided individually — such as the route for intravenous treatment or how quickly to advance the diet — are best discussed directly with your medical and nutrition team.

This article provides general medical information and cannot replace individual diagnosis or treatment. Interpretation of a pathology report and treatment planning differ from person to person, so please discuss your situation with your own healthcare team.